As of Aug 21, 2026, RGEN's PEG ratio of 0.62 reflects its valuation relative to its growth. This value reflects a P/E ratio of 241.51 measured against EPS growth of 388.5%. When benchmarked against the trailing four-quarter average of 15.0, RGEN's PEG ratio shows a 96% decrease.
Repligen's ten years historical PEG ratio averages out to 5.75. Compared to historical data, RGEN's 0.62 PEG ratio represents a decrease of 89%. RGEN reached its maximum PEG ratio of 58.47 during the Sep 2025 quarter over the past ten years. The Sep 2017 quarter had the bottom reading at 0.32, indicating the most optimal growth-adjusted valuation.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.65 | 188.34 | 289.1% |
| 2024 | N/A | N/A | -171.9% |
| 2023 | N/A | 280.94 | -80.9% |
| 2022 | 1.15 | 50.54 | 43.8% |
| 2021 | 1.09 | 113.67 | 104.4% |
| 2020 | 1.06 | 168.1 | 159.1% |
| 2019 | 13.31 | 210.23 | 15.8% |
| 2018 | N/A | 138.79 | -48.6% |
| 2017 | 0.44 | 49.03 | 111.4% |
| 2016 | 3.52 | 88.06 | 25% |
| 2015 | 8.42 | 101.04 | 12% |
| 2014 | N/A | 79.2 | -51% |
| 2013 | 2.45 | 26.75 | 10.9% |
| 2012 | N/A | 13.65 | N/A |
| 2011 | N/A | N/A | 100% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 0.47 | 181.92 | 388.5% |
| Mar 2026 | 0.4 | 128.07 | 319% |
| Dec 2025 | 0.65 | 188.34 | 289.1% |
| Sep 2025 | 58.47 | 6,683.5 | 114.3% |
| Jun 2025 | N/A | N/A | -252.9% |
| Mar 2025 | N/A | N/A | -197.7% |
| Dec 2024 | N/A | N/A | -171.9% |
| Sep 2024 | N/A | N/A | -107.7% |
| Jun 2024 | N/A | 741.53 | -92.4% |
| Mar 2024 | N/A | 427.72 | -84.5% |
| Dec 2023 | N/A | 280.94 | -80.9% |
| Sep 2023 | N/A | 87.85 | -39.7% |
| Jun 2023 | N/A | 63.15 | -22.2% |
| Mar 2023 | 11.43 | 60.56 | 5.3% |
| Dec 2022 | 1.15 | 50.54 | 43.8% |
Measured against past performance, RGEN's PEG ratio comes in under the 5 and 10-year averages.
Repligen's PEG of 0.62 is above the Healthcare sector average but below the industry average. But in comparison with its Healthcare sector average of 0.61, Repligen's PEG is only 1.6% higher.
Among its peers, RGEN has a PEG ratio below stocks GE and TMO, while higher than BMY's and NBIX's.
RGEN shows a PEG ratio of 0.62, per Aug 21, 2026 data.
RGEN shows a 5-year average PEG ratio of 7.1.
The Sep 2025 quarter marked the ten years high at 58.47 for RGEN's PEG ratio.
Currently, RGEN's PEG ratio is 89% lower than its 10-year historical average.
PEG equals PE divided by EPS growth rate (YoY TTM). As of Aug 21, 2026, Repligen carries a P/E ratio of 241.51. Earnings grew at 388.5% over the TTM period ending Jun 2026. Applying the formula, this yields a price to earnings growth ratio of 0.62. PEG RATIO(0.62) = PE RATIO(241.51) / EPS GROWTH(388.5%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.